Will Roche (RHHBY) Stock Be Helped By Santaris Pharma Acquisition?

NEW YORK (TheStreet) -- Roche Holding (RHHBY) said it will buy Santaris Pharma, a privately-held Danish biotech company, for up to $450 million in cash, according to Reuters.

Santaris develops drugs to fight liver cancer, head and neck cancer, and against metabolic and infectious diseases.

It is partly owned by Danish venture capital firm Sunstone, which earlier this year considered a U.S. listing for the company, Reuters said. 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Shares of Roche Holding are down -0.79% to $35.98.

RHHBY ChartRHHBY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone

Bank of England Holds Rates Steady, But Vote Shift Signals Hawkish Tone

Futures Fall on Further Trade Rhetoric from China and 4 Other Stories to Watch

Futures Fall on Further Trade Rhetoric from China and 4 Other Stories to Watch

5 Biggest U.S. Tech Stocks Test $4 Trillion Valuation Amid Bullish Nasdaq Run

5 Biggest U.S. Tech Stocks Test $4 Trillion Valuation Amid Bullish Nasdaq Run

Trade War Fear Creeps Back Into Markets on Thursday

Trade War Fear Creeps Back Into Markets on Thursday

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know

Trade Tussle Sinks Stocks, Oil Slides, Micron, Daimler - 5 Things You Must Know